Clinical Trial Update: Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET [Phase 4]

View source ↗

Summary

Phase 4 study investigating lanreotide in metastatic or recurrent grade I-II hindgut neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: Samsung Medical Center | Conditions: Neuroendocrine Tumors | Phase 4 | Status: UNKNOWN